[TNF-alpha inhibitors]

Rev Prat. 2003 Nov 30;53(18):1989-90.
[Article in French]
No abstract available

MeSH terms

  • Acquired Hyperostosis Syndrome / drug therapy
  • Adolescent
  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use*
  • Antirheumatic Agents / administration & dosage
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Juvenile / drug therapy*
  • Arthritis, Psoriatic / drug therapy*
  • Behcet Syndrome / drug therapy
  • Child
  • Child, Preschool
  • Clinical Trials as Topic
  • Etanercept
  • Female
  • Humans
  • Immunoglobulin G / administration & dosage
  • Immunoglobulin G / therapeutic use*
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / therapeutic use*
  • Infliximab
  • Male
  • Multicenter Studies as Topic
  • Placebos
  • Receptors, Tumor Necrosis Factor / administration & dosage
  • Receptors, Tumor Necrosis Factor / therapeutic use*
  • Sarcoidosis / drug therapy
  • Sjogren's Syndrome / drug therapy
  • Spondylitis, Ankylosing / drug therapy*
  • Time Factors
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Vasculitis / drug therapy

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Placebos
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Etanercept